Lilly’s Research Focus Narrows From Five Therapeutic Areas To Four
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly is narrowing its research focus to four therapeutic areas, CEO Sidney Taurel said
You may also be interested in...
Lilly 2005 Sales Growth Will Rest On Strength Of New Products
Sales of the eight products that Lilly has launched since November 2001 are projected to account for 20% of total sales, CFO Golden tells analysts. Lilly expects Yentreve (duloxetine) to win FDA approval for stress urinary incontinence in the first half of 2005.
Lilly 2005 Sales Growth Will Rest On Strength Of New Products
Sales of the eight products that Lilly has launched since November 2001 are projected to account for 20% of total sales, CFO Golden tells analysts. Lilly expects Yentreve (duloxetine) to win FDA approval for stress urinary incontinence in the first half of 2005.
FDA Delays PPAR Development Pending Carcinogenicity Tests, Ligand Says
The agency is requiring sponsors of PPAR agents to conduct two-year rodent carcinogenicity studies prior to entering into clinical studies longer than six months in duration. Lilly/Ligand’s naveglitazar development will be postponed between 18 and 24 months.